

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Pneumonia; staphylococcus	ADAM10	<p>Mouse studies suggest inhibiting the α-hemolysin receptor ADAM10 could help treat staphylococcal pneumonia. In mice, α-hemolysin-deficient <i>Staphylococcus aureus</i> caused less pulmonary histopathology than a wild-type <i>S. aureus</i> strain. In a model of lethal <i>S. aureus</i> pneumonia, Adam10 knockout mice had decreased lung histopathology compared with wild-type littermates. Next steps include identifying additional targets that could help treat or prevent <i>S. aureus</i> α-hemolysin-mediated disease.</p> <p>SciBX 4(37); doi:10.1038/scibx.2011.1045 Published online Sept. 22, 2011</p>	<p>Patent applications filed covering targeting of α-hemolysin-mediated processes; available for licensing from The University of Chicago Office of Technology and Intellectual Property</p>	<p>Inoshima, I. <i>et al. Nat. Med.</i>; published online Sept. 18, 2011; doi:10.1038/nm.2451 Contact: Juliane Bubeck Wardenburg, The University of Chicago, Chicago, Ill. e-mail: jbubeckw@peds.bsd.uchicago.edu</p>